Mylan Announces STALEVO® Settlement Agreement

                Mylan Announces STALEVO® Settlement Agreement

PR Newswire

PITTSBURGH, July 25, 2013

PITTSBURGH, July 25, 2013 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
confirmed that Mylan Pharmaceuticals Inc. ("Mylan") and Orion Corporation have
entered into a settlement and license agreement settling the parties
litigation in connection with Mylan's filing of an Abbreviated New Drug
Application (ANDA) with the U.S. Food and Drug Administration (FDA) for
Carbidopa/Levodopa/Entacapone Tablets, 12.5 mg/50 mg/200 mg, 18.75 mg/75
mg/200 mg, 25 mg/100 mg/200 mg, 31.25 mg/125 mg/200 mg, 37.5 mg/150 mg/200 mg,
and 50 mg/200 mg/200 mg. This product is the generic version of STALEVO^®,
which is indicated to treat patients with idiopathic Parkinson's disease to
substitute (with equivalent strength of each of the three components) for
immediate-release Carbidopa/Levodopa and Entacapone previously administered as
individual products.

Under the terms of the settlement and license agreement, Mylan may launch an
authorized generic version of STALEVO immediately and its own ANDA product
upon receiving final FDA approval. Pursuant to the agreement, the parties
pending litigation will be dismissed. All other terms and conditions of the
settlement and license agreement are confidential, and the agreement itself is
subject to review by the U.S. Department of Justice and the Federal Trade

For the 12 months ending March 31, 2013, STALEVO had U.S. sales of
approximately $138.6 million, according to IMS Health.

Currently, Mylan has 174 ANDAs pending FDA approval representing $83.2 billion
in annual sales, according to IMS Health. Thirty-seven of these pending ANDAs
are potential first-to-file opportunities, representing $23 billion in annual
brand sales, for the 12 months ending Dec. 31, 2012, according to IMS Health.

This press release includes statements that constitute "forward-looking
statements," including with regard to the settlement of the litigation and
sales of the product. These statements are made pursuant to the safe harbor
provisions of the Private Securities Litigation Reform Act of 1995. Because
such statements inherently involve risks and uncertainties, actual future
results may differ materially from those expressed or implied by such
forward-looking statements. Factors that could cause or contribute to such
differences include, but are not limited to: any legal or regulatory
challenges to the settlement; strategies by competitors or other third parties
to delay or prevent product introductions; risks inherent in legal and
regulatory processes; and the other risks detailed in the company's filings
with the Securities and Exchange Commission. The company undertakes no
obligation to update these statements for revisions or changes after the date
of this release.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of approximately 1,100 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside.

SOURCE Mylan Inc.

Contact: Nina Devlin (Media), 724.514.1968, Kris King (Investors),
Press spacebar to pause and continue. Press esc to stop.